Literature DB >> 22617589

First-trimester prediction of preeclampsia in nulliparous women at low risk.

Leslie Myatt1, Rebecca G Clifton, James M Roberts, Catherine Y Spong, John C Hauth, Michael W Varner, John M Thorp, Brian M Mercer, Alan M Peaceman, Susan M Ramin, Marshall W Carpenter, Jay D Iams, Anthony Sciscione, Margaret Harper, Jorge E Tolosa, George Saade, Yoram Sorokin, Garland D Anderson.   

Abstract

OBJECTIVE: To identify clinical characteristics and biochemical markers in first-trimester samples that would possibly predict the subsequent development of preeclampsia.
METHODS: We conducted a multicenter observational study in 2,434 nulliparous women at low risk to identify biomarkers that possibly predict preeclampsia. Clinical history, complete blood count, and biochemical markers were assessed in the first trimester. The trophoblast and angiogenesis markers ADAM-12, pregnancy-associated plasma protein-A, placental protein 13, placental growth factor, soluble fms-like tyrosine kinase-1, and endoglin were measured in a case-control subset of 174 women with preeclampsia and 509 women in the control group.
RESULTS: Univariable analysis revealed maternal age, race, marital status, years of education, source of medical payment, prenatal caregiver, body mass index (BMI, calculated as weight (kg)/[height (m)]), and systolic blood pressure at enrollment were significantly associated with preeclampsia. Mean platelet volume was greater at enrollment in women who later had development of preeclampsia (median 9.4 compared with 9.0 femtoliter (fl); P=.02). First-trimester concentrations (multiples of the median) of ADAM-12 (1.14 compared with 1.04; P=.003), pregnancy-associated plasma protein-A (0.94 compared with 0.98; P=.04), and placental growth factor (0.83 compared with 1.04; P<.001) were significantly different in women who had development of preeclampsia compared with women in the control group. The optimal multivariable model included African American race, systolic blood pressure, BMI, education level, ADAM-12, pregnancy-associated plasma protein-A, and placental growth factor, and yielded an area under the curve of 0.73 (95% confidence interval 0.69-0.77) and a sensitivity of 46.1% (95% confidence interval 38.3-54.0) for 80% specificity.
CONCLUSION: A multivariable analysis of clinical data and biochemical markers in the first trimester did not identify a model that had clinical utility for predicting preeclampsia in a nulliparous population at low risk. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617589      PMCID: PMC3360523          DOI: 10.1097/AOG.0b013e3182571669

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  34 in total

1.  Duration of sexual relationship and its effect on preeclampsia and small for gestational age perinatal outcome.

Authors:  Ee Min Kho; Lesley M E McCowan; Robyn A North; Claire T Roberts; Eliza Chan; Michael A Black; Rennae S Taylor; Gustaaf A Dekker
Journal:  J Reprod Immunol       Date:  2009-08-12       Impact factor: 4.054

2.  Mean platelet volume is associated with insulin resistance in non-obese, non-diabetic patients with coronary artery disease.

Authors:  Ercan Varol; Selahattin Akcay; Mehmet Ozaydin; Dogan Erdogan; Abdullah Dogan; Ahmet Altinbas
Journal:  J Cardiol       Date:  2010-04-28       Impact factor: 3.159

3.  Mean platelet volume in patients with prehypertension and hypertension.

Authors:  Ercan Varol; Selahattin Akcay; Atilla Icli; Habil Yucel; Emel Ozkan; Dogan Erdogan; Mehmet Ozaydin
Journal:  Clin Hemorheol Microcirc       Date:  2010       Impact factor: 2.375

4.  Vitamins C and E to prevent complications of pregnancy-associated hypertension.

Authors:  James M Roberts; Leslie Myatt; Catherine Y Spong; Elizabeth A Thom; John C Hauth; Kenneth J Leveno; Gail D Pearson; Ronald J Wapner; Michael W Varner; John M Thorp; Brian M Mercer; Alan M Peaceman; Susan M Ramin; Marshall W Carpenter; Philip Samuels; Anthony Sciscione; Margaret Harper; Wendy J Smith; George Saade; Yoram Sorokin; Garland B Anderson
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes.

Authors:  Anastasia Stamatopoulou; Nicholas J Cowans; Elisabet Matwejew; Constantine von Kaisenberg; Kevin Spencer
Journal:  Hypertens Pregnancy       Date:  2010-08-11       Impact factor: 2.108

6.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield
Journal:  Arch Intern Med       Date:  2003-02-24

7.  Prediction model for hypertension in pregnancy in nulliparous women using information obtained at the first antenatal visit.

Authors:  Marie-Elise Nijdam; Kristel J M Janssen; Karel G M Moons; Diederick E Grobbee; Joris A van der Post; Michiel L Bots; Arie Franx
Journal:  J Hypertens       Date:  2010-01       Impact factor: 4.844

8.  Platelet activation in normotensive and hypertensive pregnancies complicated by intrauterine growth retardation.

Authors:  L A Norris; B L Sheppard; G Burke; J Bonnar
Journal:  Br J Obstet Gynaecol       Date:  1994-03

9.  Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.

Authors:  Leona C Y Poon; Violeta Stratieva; Silvia Piras; Solmaz Piri; Kypros H Nicolaides
Journal:  Prenat Diagn       Date:  2010-03       Impact factor: 3.050

10.  Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort.

Authors:  Robyn A North; Lesley M E McCowan; Gustaaf A Dekker; Lucilla Poston; Eliza H Y Chan; Alistair W Stewart; Michael A Black; Rennae S Taylor; James J Walker; Philip N Baker; Louise C Kenny
Journal:  BMJ       Date:  2011-04-07
View more
  59 in total

1.  Cell-Free Total and Fetal DNA in First Trimester Maternal Serum and Subsequent Development of Preeclampsia.

Authors:  Robert M Silver; Leslie Myatt; John C Hauth; Kenneth J Leveno; Alan M Peaceman; Susan M Ramin; Philip Samuels; George Saade; Yoram Sorokin; Rebecca G Clifton; Uma M Reddy
Journal:  Am J Perinatol       Date:  2016-07-11       Impact factor: 1.862

2.  A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b).

Authors:  David M Haas; Corette B Parker; Deborah A Wing; Samuel Parry; William A Grobman; Brian M Mercer; Hyagriv N Simhan; Matthew K Hoffman; Robert M Silver; Pathik Wadhwa; Jay D Iams; Matthew A Koch; Steve N Caritis; Ronald J Wapner; M Sean Esplin; Michal A Elovitz; Tatiana Foroud; Alan M Peaceman; George R Saade; Marian Willinger; Uma M Reddy
Journal:  Am J Obstet Gynecol       Date:  2015-01-31       Impact factor: 8.661

3.  Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia.

Authors:  Caitlin J Smith; Audrey F Saftlas; Cassandra N Spracklen; Elizabeth W Triche; Andrew Bjonnes; Brendan Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman
Journal:  Am J Hypertens       Date:  2015-05-23       Impact factor: 2.689

4.  Importance of Early Diagnosis in Peripartum Cardiomyopathy.

Authors:  Jennifer Lewey; Lisa D Levine; Michal A Elovitz; Olga C Irizarry; Zoltan Arany
Journal:  Hypertension       Date:  2019-11-11       Impact factor: 10.190

Review 5.  First trimester screening for pre-eclampsia.

Authors:  Stefan C Kane
Journal:  Obstet Med       Date:  2016-05-14

6.  Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy.

Authors:  Stacy Zamudio; Marcus Borges; Lourdes Echalar; Olga Kovalenko; Enrique Vargas; Tatiana Torricos; Abdulla Al Khan; Manuel Alvarez; Nicholas P Illsley
Journal:  Biol Reprod       Date:  2014-02-27       Impact factor: 4.285

7.  The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population.

Authors:  Leslie Myatt; Rebecca G Clifton; James M Roberts; Catherine Y Spong; John C Hauth; Michael W Varner; Ronald J Wapner; John M Thorp; Brian M Mercer; William A Grobman; Susan M Ramin; Marshall W Carpenter; Philip Samuels; Anthony Sciscione; Margaret Harper; Jorge E Tolosa; George Saade; Yoram Sorokin; Garland D Anderson
Journal:  Obstet Gynecol       Date:  2012-10       Impact factor: 7.661

8.  Descriptive epidemiology of chronic hypertension, gestational hypertension, and preeclampsia in New York State, 1995-2004.

Authors:  David A Savitz; Valery A Danilack; Stephanie M Engel; Beth Elston; Heather S Lipkind
Journal:  Matern Child Health J       Date:  2014-05

9.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

10.  Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?

Authors:  L Myatt; R G Clifton; J M Roberts; C Y Spong; R J Wapner; J M Thorp; B M Mercer; A M Peaceman; S M Ramin; M W Carpenter; A Sciscione; J E Tolosa; G Saade; Y Sorokin; G D Anderson
Journal:  BJOG       Date:  2013-01-18       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.